A little more than a month after completing its big asset swap with GlaxoSmithKline, Novartis CEO Joe Jimenez says he's going back to the bargaining table to look for some bolt-on buyouts in the $2 billion to $5 billion range.
Novartis beat profit estimates for the first quarter, partly because of the big deal closing with GlaxoSmithKline March 2. Now, CEO Joe Jimenez says the Swiss drugmaker is back on the dealmaking trail.
Readying itself for what looks like a blockbuster victory lap in the cardiovascular field, Novartis has notched boasting rights for its heart drug LCZ696, gaining recognition in the U.K. as a "promising innovative medicine" that could be made available to patients ahead of formal marketing approval.
Australia's CSL will launch its new global flu vaccine business in early 2016, after it completes its $275 million acquisition of Novartis' flu vaccine unit.
Eli Lilly's closely watched autoimmune treatment ixekizumab met its main goals in a Phase III psoriatic arthritis trial, rolling toward an FDA application and a shot at competing in a fast-crowding space.
A novel immuno-oncology treatment from Novartis and the University of Pennsylvania came through in an early safety study on patients with solid tumors, encouraging investigators and burnishing its potential.
Novartis' Alcon received FDA approval for its implantable AcrySof IQ ReSTOR +2.5 Diopter intraocular lens, enabling vision correction at all distances in eye care patients with or without presbyopia who undergo cataract surgery.
Fitch Ratings is raising the flag on pharma M&A. The credit ratings agency says the current spate of dealmaking is putting some pressure on European Big Pharma players.
The U.S. drug market is the largest in the world and just about every drugmaker wants the biggest piece of it that it can get. For 2014 that honor goes to biotech Gilead Sciences, whose hep C drugs vaulted it to the top, according to PMLiVE based on sales info from GlobalData.
Novartis already has some positive data for Arzerra, a chronic lymphocytic leukemia (CLL) drug it picked up in its $16 billion buyout of GlaxoSmithKline's cancer drugs. Given the competition in the category, Novartis can use whatever boost it can get as it works to extract additional sales out of the portfolio of oncology products.